A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

Key Points • Lenalidomide, obintuzumab, and CHOP chemotherapy are efficacious and well tolerated treatments for newly diagnosed DLBCL.• LO-CHOP led to high molecular response rates based on circulating tumor DNA sequencing during and after treatment in this phase 1b/2 study.

[1]  Y. Oki,et al.  Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Greil,et al.  Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[3]  L. Staudt,et al.  Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. , 2021, Cancer cell.

[4]  J. Burke,et al.  ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) , 2021 .

[5]  Ash A. Alizadeh,et al.  Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA , 2021, Nature Biotechnology.

[6]  J. Burke,et al.  First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL. , 2021 .

[7]  Ash A. Alizadeh,et al.  Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Paul M. Rindler,et al.  Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology , 2021, Nature Biotechnology.

[9]  R. Gascoyne,et al.  ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Scott,et al.  Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Jardin,et al.  Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Westin,et al.  Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma , 2021, Leukemia & lymphoma.

[13]  O. O’Connor,et al.  A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise. , 2020, The Lancet. Haematology.

[14]  Ryan D. Morin,et al.  A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. , 2020, Cancer cell.

[15]  Ash A. Alizadeh,et al.  Integrating genomic features for non-invasive early lung cancer detection , 2020, Nature.

[16]  R. Gascoyne,et al.  Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies , 2019, Blood.

[17]  R. Houot,et al.  Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study. , 2019, The Lancet. Haematology.

[18]  S. Barrans,et al.  Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial , 2019, The Lancet. Oncology.

[19]  L. Staudt,et al.  Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Gribben,et al.  AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Houot,et al.  Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study , 2018, Leukemia.

[22]  G. Salles,et al.  Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma , 2018, The New England journal of medicine.

[23]  Ash A. Alizadeh,et al.  Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Tarte,et al.  NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment , 2017, Oncoimmunology.

[25]  W. Klapper,et al.  Obinutuzumab for the First‐Line Treatment of Follicular Lymphoma , 2017, The New England journal of medicine.

[26]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[27]  J. Burke,et al.  Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Greil,et al.  Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  L. Staudt,et al.  A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2017, Clinical Cancer Research.

[30]  R. Gascoyne,et al.  CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Gribben,et al.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. , 2016, The Lancet. Oncology.

[32]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[33]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Á. Payer,et al.  Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells , 2014, BioMed research international.

[35]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[36]  C. Klein,et al.  Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models , 2013, Molecular Cancer Therapeutics.

[37]  Paul Shinn,et al.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.

[38]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[39]  B. Coiffier,et al.  Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.

[40]  C. Klein,et al.  Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. , 2010, Blood.

[41]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[42]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.